Cussenot O, et al. - Preliminary results of a pilot series at 2 French urology centers in low-risk prostate cancer (LRPC) pts receiving 2 drugs (analogs and 5-alpha-reductase inhibitor) for 3 months (mo), demonstrated tumor regression in about 60% of cases and suggested that LRPC could be reversed by androgen deprivation therapy (ADT). Experts sought to confirm these results on a larger scale. As per the data obtained with the 3mo of Leuprorelin for LRPC, DT could be used to reverse LRPC lesions, thereby improving the results obtained with subsequent active surveillance (AS). At 9 months, early ADT led to a better quality of life. The detection of hidden aggressive disease was also allowed by this strategy.